 | Up a level |
Journal Article
Eichhorst, Barbara, Fink, Anna Maria, Busch, Raymonde, Kovacs, Gabor, Maurer, Christian, Lange, Elisabeth, Koeppler, Hubert, Kiehl, Michael G., Soekler, Martin, Schlag, Rudolf, Vehling-Kaiser, Ursula, Koechling, Georg R. A., Ploeger, Christoph, Gregor, Michael, Plesner, Torben, Trneny, Marek, Fischer, Kirsten, Doehner, Hartmut, Kneba, Michael, Wendtner, Clemens-Martin, Klapper, Wolfram, Kreuzer, Karl Anton, Stilgenbauer, Stephan, Boettcher, Sebastian and Hallek, Michael (2014). Frontline Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Shows Superior Efficacy in Comparison to Bendamustine (B) and Rituximab (BR) in Previously Untreated and Physically Fit Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Final Analysis of an International, Randomized Study of the German CLL Study Group (GCLLSG) (CLL10 Study). Blood, 124 (21). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020
Langerbeins, Petra, Bahlo, Jasmin, Rhein, Christina, Cramer, Paula, Pflug, Natali, Fischer, Kirsten, Stilgenbauer, Stephan, Kreuzer, Karl Anton, Wendtner, Clemens-Martin, Eichhorst, Barbara and Hallek, Michael (2015). The CLL12 trial protocol: a placebo-controlled double-blind Phase III study of ibrutinib in the treatment of early-stage chronic lymphocytic leukemia patients with risk of early disease progression. Future Oncol., 11 (13). S. 1895 - 1904. LONDON: FUTURE MEDICINE LTD. ISSN 1744-8301
Pallasch, Christian P. 
ORCID: 0000-0001-5675-6905, Leskov, Ilya, Braun, Christian J., Vorholt, Daniela, Drake, Adam, Soto-Feliciano, Yadira M., Bent, Eric H., Schwamb, Janine, Iliopoulou, Bettina, Kutsch, Nadine, van Rooijen, Nico, Frenzel, Lukas P., Wendtner, Clemens M., Heukamp, Lukas ORCID: 0000-0002-3388-3482, Kreuzer, Karl Anton, Hallek, Michael, Chen, Jianzhu and Hemann, Michael T.
(2014).
Sensitizing Protective Tumor Microenvironments to Antibody-Mediated Therapy.
Cell, 156 (3).
S. 590 - 603.
CAMBRIDGE:
CELL PRESS.
ISSN 1097-4172